The company highlighted three primary growth drivers: plozasiran, obesity programs, and the emerging CNS pipeline. Plozasiran ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for my updated look at ARWR stock.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) said the FDA has accepted its New Drug Application for its drug plozasiran for the ...